The VITamin D and OmegA-3 TriaL (VITAL) is a 5-year, randomized, double-blind, placebo-controlled trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D (2000 IU) or fish oil (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people without a prior history of these illnesses. Ancillary studies are evaluating the effect of vitamin D and omega-3 fatty acid supplementation on other outcomes, including diabetes, hypertension, heart failure, cognitive decline, autoimmune diseases (e.g., thyroid disease, rheumatoid arthritis, and lupus), physical disability and falls, bone health and fractures, anemia, macular degeneration, dry eye syndrome, infections, asthma, depression, diabetes-related kidney disease, kidney function in people with hypertension, chronic knee pain symptoms, atrial fibrillation, and others.
To learn more about VITAL, please click on the following links:
VITAL Study
(VITamin D and OmegA-3 TriaL)
Principal Investigators: Dr. JoAnn E. Manson,
The VITamin D and OmegA-3 TriaL (VITAL) is a 5-year, randomized, double-blind, placebo-controlled trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D (2000 IU) or fish oil (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people without a prior history of these illnesses. Ancillary studies are evaluating the effect of vitamin D and omega-3 fatty acid supplementation on other outcomes, including diabetes, hypertension, heart failure, cognitive decline, autoimmune diseases (e.g., thyroid disease, rheumatoid arthritis, and lupus), physical disability and falls, bone health and fractures, anemia, macular degeneration, dry eye syndrome, infections, asthma, depression, diabetes-related kidney disease, kidney function in people with hypertension, chronic knee pain symptoms, atrial fibrillation, and others.
To learn more about VITAL, please click on the following links: